翰宇药业12月29日获融资买入2540.95万元，融资余额11.92亿元

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Hanyu Pharmaceutical, indicating a decline in stock price and significant changes in financing activities [1][2] - On December 29, Hanyu Pharmaceutical's stock fell by 0.75%, with a trading volume of 368 million yuan, and a net financing outflow of 28.43 million yuan [1] - As of December 29, the total margin balance for Hanyu Pharmaceutical was 1.193 billion yuan, with the financing balance accounting for 7.26% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Hanyu Pharmaceutical reached 110,100, an increase of 74.86% from the previous period, while the average circulating shares per person decreased by 42.81% [2] - For the period from January to September 2025, Hanyu Pharmaceutical reported a revenue of 683 million yuan, representing a year-on-year growth of 82.06%, and a net profit attributable to shareholders of 71.35 million yuan, up 305.00% year-on-year [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends paid in the last three years [2]